TOKYO, Mar 24 (Pulse News Wire) – Taiko Pharmaceutical CO.,LTD. (4574.T) entered an improvement period due to non-compliance with listing standards as of December 31, 2025.
The company confirmed its non-compliance with the "circulating stock market value" criterion set by Prime Shijou, falling below the threshold of ¥10.00 billion. However, Taiko plans to meet the criteria by the end of 2026 through various initiatives aimed at enhancing its market valuation. In previous assessments, Taiko had met all listing requirements except for the circulating stock market value criterion as of December 31, 2023. By implementing corrective measures, the company achieved compliance with all criteria by December 31, 2024.
To address the current non-compliance issue, Taiko will focus on several strategies, including expanding supply and demand in pharmaceutical operations, strategic investments in new products and businesses, optimizing capital cost management, fostering organizational culture changes, and reinforcing shareholder returns and investor relations activities. Specifically, the company aims to enhance its product portfolio by strengthening brand equity globally, particularly in Asia, while also developing new products to increase sales ratios. Additionally, Taiko plans to resume dividend payments starting from the fiscal year ending December 2025, targeting a dividend payout ratio of DOE2.0% or higher by the fiscal year ending December 2026, and DOE3.0% or higher by the fiscal year ending December 2028. Should Taiko fail to comply with the listing standards by the next review date of December 31, 2026, it faces potential designation as a monitored stock (under review) and subsequent delisting from the Prime Market as early as July 1, 2027.
🟢 Confidence: High AI-translated content.